

NAME OF THE MEDICINAL PRODUCT Oki 0.16% oromucosal spray. **QUALITATIVE AND QUANTITATIVE COMPOSITION.** 100 ml of oromucosal spray contain: active ingredient : ketoprofen lysine salt 0.16 g equal to 0.10 g ketoprofen. For excipients: see 6.1. **PHARMACEUTICAL FORM.** Oromucosal spray. **CLINICAL PARTICULARS.** **Therapeutic indications.** Symptomatic treatment of irritative-inflammatory conditions even associated with pain of the oro-pharyngeal cavity (e.g. gingivitis, stomatitis, pharyngitis) even as consequence of preservative or extractive dental therapy. **Posology and method of administration.** 1-2 sprays up to 3 times daily or following different medical prescription, directly on the area involved. Each spray gives 0.2 ml solution, equal to 0.32 mg active ingredient. **Contraindications.** Oki 0.16% oromucosal spray should not be administered in case of hypersensitivity to the active ingredient, to other non steroid antiphlogistic drugs (NSAIDs) or to any of the excipients, to patients in whom substances with analogous mechanism of action (e.g. acetylsalicylic acid or other NSAIDs) cause asthma attacks, bronchospasm, acute rhinitis as well as nasal polyps, urticaria or angioneurotic edema, in case of progressed bronchial asthma, during pregnancy and lactation. **Special warnings and special precautions for use.** The – especially prolonged – use of topical products might give rise to sensitisation phenomena: in this case, treatment should be discontinued and proper therapeutic provisions should be taken. **Interactions with other medicinal products and other forms of interaction.** At present, no interactions are known with other drugs: interactions may be excluded, even in consideration of the route of administration and of the dosage of drug given. **Pregnancy and lactation.** Like other non steroid antiphlogistic drugs, the product should not be used during ascertained or presumed pregnancy and during lactation. **Effects on ability to drive and use machines.** No effects are known on the ability to drive and use machines: such effects may be excluded in consideration of the route of administration and of the dosage of drug given. **Undesirable effects.** Local undesirable effects after the topical administration on the oral mucosa of ketoprofene lysine salt solution are extremely rare and consist in irritative or allergic phenomena (angioneurotic edema), mainly in subjects with hypersensitivity to NSAIDs. Nevertheless, no systemic undesirable effects have arisen in consideration of the route of administration and of the dosage of drug given. **Overdose:** At present, no case of overdose is known even considering the amount of active ingredient that does not allow an accidental overdose. **PHARMACOLOGICAL PROPERTIES.**

Pharmacodynamic properties. Pharmacotherapeutic class: Stomatologic drugs. Other substances for the local oral treatment. ATC code: A01AD11. Ketoprofen lysine salt is the lysine salt of 2-(3-benzoylphenyl) propionic acid, an analgesic, antiphlogistic and antipyretic drug belonging to the class of NSAIDs. Ketoprofen lysine salt is more soluble than ketoprofen acid. The mechanism of action of NSAIDs is related to the reduction of the synthesis of prostaglandins through inhibition of the cyclo-oxygenase enzyme. More specifically, an inhibition is observed of the transformation of the arachidonic acid into the cyclic endoperoxydes PGG₂ and PGH₂, precursors of the prostaglandins PGE₁, PGE₂, PGF_{2a} and PGD₂ and even of the prostacyclin PGI₂ and of the thromboxanes (TxA₂ and TxB₂). Furthermore, the synthesis of prostaglandins may interfere with other mediators, such as quinines, causing an indirect action that would add itself to the direct one. Ketoprofen lysine salt is provided with a marked analgesic effect, that is linked with both its antiphlogistic and a central effect.

Pharmacokinetic properties. After the use in humans of a dose of ketoprofen lysine salt (160 mg) in the mouth-wash formulation, the haematic levels of ketoprofen achieved are very low (lower than 400 ng/ml) and insufficient to provide systemic pharmacological effects. Ketoprofen is eliminated very rapidly, mainly through the kidney: 50% of the systemically given product is secreted in the urines in 6 hours. Ketoprofen is widely metabolized: about 60-80% of the systemically given product is found as metabolites in the urines.

Preclinical safety data. The active ingredient is little toxic: according to the routes of administration, its DL₅₀ is about 300 mg/kg in the rat, equal to 80-100 times the active dose as antiphlogistic and analgesic drug. The product is not teratogenic and is not chemically linked with drugs with cancerogenic effect.

PHARMACEUTICAL PARTICULARS.

List of excipients. 85% glycerol, xylitol, methyl-parahydroxybenzoate, monobasic sodium phosphate, poloxamer 407, mint aroma, purified water.

Incompatibilities. None.

Shelf-life. Oki 0.16% oromucosal spray has a shelf-life of 2 years.

Special precautions for storage. None.

Nature and contents of container. Litographed carton box containing 1 HDPE plastic bottle to 20 ml, containing 15 ml solution, with spray pump able to give about 200 ml of solution, cannula and distribution valve.

Instructions for use. Rise the cannula. Introduce the cannula in the mouth and spray towards the area involved. Spray the solution by pressing the distribution valve.